Chiral Quest Subsidiary Signs License Agreement with
News Sep 27, 2005
VioQuest's subsidiary Chiral Quest, Inc., (VQPH) signed a licensing agreement granting Merck & Co., Inc. use of its catalysts for the process development and manufacture of single-enantiomer intermediates and active pharmaceutical ingredients.
This agreement provides Merck with access to a broad range of proprietary ligands and catalysts.
Two proteins that activate the fastest molecule in our nerve cells have been identified by researchers at University of Warwick. This mechanism is responsible for transport through our nervous system. This finding could lead to a new therapeutic treatments for people with hereditary spastic paraplegia and other neurological disorders.READ MORE